A receptor could hold the key to explaining how stress affects behavior, at least under certain circumstances. Scientists from the Korea Advanced Institute of Science and Technology (KAIST) have described how childhood neglect or abuse altered the brain. Stress glucocorticoid hormones caused neuronal damage in mice by increasing the receptor tyrosine kinase MERTK in astrocytes and inducing them to phagocytose excitatory synapses. Read More
Swiss researchers have gained new insights into the relationship between aging, inflammation, neurodegeneration and cognitive decline. EPFL professor Andrea Ablasser and her team showed that brain aging was driven by microglial activation of the cGAS/STING pathway. Read More
Entrada Therapeutics Inc. has received authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its CTIMP (clinical trial of an investigational medicinal product) application for a phase I clinical trial in healthy volunteers for ENTR-601-44. Read More
Researchers from Laboratoire Biodim presented the discovery of novel HIV-1 integrase-LEDGF allosteric inhibitors (INLAIs), designed to share the binding site on the viral protein with the host factor LEDGF/p75. INLAIs act as molecular glues to promote hyper-multimerization of HIV-1 integrase protein to produce defective progeny virions, and as such, severely disrupt maturation of viral particles. Read More
Recludix Pharma Inc. has disclosed signal transducer and activator of transcription 3 (STAT3) and/or STAT6 inhibitors reported to be useful for the treatment of cancer and inflammatory disorders. Read More
Guangzhou Kaishi Pharmaceutical Co. Ltd. has patented treprostinil derivatives acting as nitric oxide (NO) donors reported to be useful for the treatment of acute respiratory distress syndrome, pulmonary arterial hypertension and arterial occlusion. Read More
Lexeo Therapeutics Inc. has announced that its IND for LX-2020 has been cleared by the FDA. LX-2020 is an AAVrh10-based gene therapy candidate designed to intravenously deliver a functional PKP2 gene to cardiac muscle for the treatment of arrhythmogenic cardiomyopathy (ACM) caused by variants in PKP2 (PKP2-ACM). Read More
Mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors have been reported in an Immuneering Corp. patent as potentially useful for the treatment of cancer. Read More
Research at Genfleet Therapeutics Inc. has led to the development of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer. Read More
Amygdala Neurosciences Inc. has been awarded a $2.0 million NIH grant to support IND-enabling and early-stage development of its selective, reversible, orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor ANS-858 to treat alcohol use disorder (AUD). Read More
The FDA has cleared Qualigen Therapeutics Inc.’s IND application for QN-302, a potential best-in-class small molecule G-Quadruplex (G4)-selective transcription inhibitor. Read More
